NR-52287_SARS相关冠状病毒2,隔离USA-WA1/2020,伽马辐照(灭活生物体)

NR-52287 consists of a crude preparation of cell lysate and supernatant from Cercopithecus aethiops kidney epithelial cells (Vero E6; ATCC ? CRL-1586?) infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 that was gamma-irradiated (5 × 106 RADs) on dry ice, followed by sonication.
SARS-CoV-2, isolate USA-WA1/2020 was isolated from an oropharyngeal swab from a patient with a respiratory illness who had recently returned from travel to the affected region of China and developed clinical disease (COVID-19) in January 2020 in Washington, USA.
The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced (the isolate - GenBank: MN985325 and GISAID: EPI_ISL_404895 and after one passage in Vero cells - GenBank: MT020880). The complete genome of SARS-CoV-2, USA-WA1/2020 has been sequenced after four passages in Vero cells in collaboration with Database for Reference Grade Microbial Sequences (FDA-ARGOS; GenBank: MT246667).
Intended Use:
NR-52287 is intended for use in molecular assays or can be used as a process (work-flow) control (for example: viral RNA extraction through qPCR amplification process). Please refer to the Certificate of Analysis for pre-inactivation infectious titer and post-inactivated genome equivalence (GE) quantification by Droplet Digital PCR for your specific lot. The GE value is contributed by amplification of genome fragments and should be treated as an estimate for end-users to qualify assays on their platform. NR-52287 can also be used to make a dilution series to estimate level of detection. However, this product is not suitable as a whole cell antigen preparation because the protein content is largely contributed by the host cell and the fetal bovine serum used during virus propagation.
Each vial contains approximately 0.5 mL of gamma-irradiated and sonicated cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA-WA1/2020.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立,旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中,可以监控科学界对这些材料的访问和使用,并确保试剂的质量控制。
除了为传染病界提供材料外,BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势,包括安全存储、社区访问和分发;同时保护存款人的知识产权。只要有需要,BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月, ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料,包括由其他政府支持的研究项目存放的材料,将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中,涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
